Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2017, Article ID 5384091, 9 pages
https://doi.org/10.1155/2017/5384091
Research Article

Serum Autoantibodies against STIP1 as a Potential Biomarker in the Diagnosis of Esophageal Squamous Cell Carcinoma

1Department of Clinical Laboratory Medicine, Cancer Hospital, Shantou University Medical College, Shantou 515041, China
2Department of Biochemistry and Molecular Biology, Shantou University Medical College, Shantou 515041, China
3The Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area of Guangdong Higher Education Institutes, Shantou University Medical College, Shantou 515041, China
4Shantou University Medical College, Shantou 515041, China
5Department of Radiation Oncology, Cancer Hospital, Shantou University Medical College, Shantou 515041, China
6Department of Oncological Research Laboratory, Cancer Hospital, Shantou University Medical College, Shantou 515041, China
7Department of Surgical Oncology, Cancer Hospital, Shantou University Medical College, Shantou 515041, China
8Institute of Oncologic Pathology, Shantou University Medical College, Shantou 515041, China

Correspondence should be addressed to Yu-Hui Peng; moc.361@666iuhuygnep and En-Min Li; nc.ude.uts@ilmn

Received 9 May 2017; Revised 10 July 2017; Accepted 16 July 2017; Published 9 August 2017

Academic Editor: Stamatios E. Theocharis

Copyright © 2017 Yi-Wei Xu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Esophageal squamous cell carcinoma (ESCC) remains one of the leading causes of cancer-related mortality around the world. The identification of novel serum biomarkers is required for early detection of ESCC. This study was designed to elucidate whether autoantibodies against STIP1 could be a diagnostic biomarker in ESCC. An enzyme-linked immunosorbent assay was performed to detect serum levels of STIP1 autoantibodies in a training cohort (148 ESCC patients and 111 controls) and a validation cohort (60 ESCC patients and 40 controls). Mann–Whitney’s U test showed that ESCC patients in two cohorts have higher levels of autoantibodies against STIP1 when compared to controls (). According to receiver operating characteristic analysis, the sensitivity, specificity, and area under the curve (AUC) of autoantibodies against STIP1 in ESCC were 41.9%, 90.1%, and 0.682 in the training cohort and 40.0%, 92.5%, and 0.710 in the validation cohort, respectively. Moreover, detection of autoantibodies against STIP1 could discriminate early-stage ESCC patients from controls, with sensitivity, specificity, and AUC of 35.7%, 90.1%, and 0.684 in the training cohort and 38.5%, 92.5%, and 0.756 in the validation cohort, respectively. Our findings indicated that autoantibodies against STIP1 might be a useful biomarker for early-stage ESCC detection.